Dr. Criscitiello is Assitant Professor at the University of Milan and medical oncologist appointed with High Specialty in Immunotherapy at the Division of Experimental Therapeutics, European Institute of Oncology – Milano, Italy.

She is a clinician and researcher committed on early drug development for patients with solid tumors, with a special interest in breast cancer. She is the global principal investigator of the international and multicentric ALPHABET study: A Randomized phase III trial of trastuzumab + ALPelisib +/- endocrine therapy versus trastuzumab + Chemotherapy in PIK3CA mutated HER2+ Advanced BrEasT cancer patients previously treated.

She is member of the ESMO Breast Cancer Faculty since 2017, Deputy Chair of the ESMO Leadership Generation Task Force since 2020, Member of the ESMO Press & Media Affairs Committee since 2018, and AIOM Breast Cancer Guidelines Panel Member since 2018. She serves as Associate Editor of the Frontiers in Oncology and ESMO Open – Cancer Horizons.

She serves as reviewer for several scientific journals, including Lancet Oncology, Annals of Oncology, European Journal of Cancer, Journal of Translational Medicine, The Breast, The Oncologist, NPJ. She has authored 130 peer-reviewed publications, with H-index = 34. She is speaker at numerous national and international meetings.